Renee B. Appel

Blogs: BioLoquitur, Consumer Class Defense Blog, The Blunt Truth

Latest Articles

FTC Issues Additional Three Warning Letters to CBD Companies

By Tonya M. Esposito, Renee B. Appel & Jonathan Huie on September 17, 2019

On September 10, 2019, the Federal Trade Commission (FTC) sent warning letters to three companies that sold cannabidiol (CBD) products marketed with misleading claims that they could treat serious diseases. The FTC aims to “protect consumers from unfair and deceptive practices in the marketplace,” and accordingly has the responsibility of jointly overseeing marketing and advertising of products that fall under the U.S. Food & Drug Administration’s control. (In 2019, the FDA issued four warning letters, and publicly disclosed…

The Blunt Truth

National Credit Union Administration Issues Statement About Serving Hemp Businesses

By Tonya M. Esposito & Renee B. Appel on September 10, 2019

Following last year’s passage of the 2018 Farm Bill, the National Credit Union Administration (NCUA) issued a regulatory update in August of 2019 to federally insured credit unions. Citing growth in hemp-related commerce, the NCUA emphasized the need for credit unions to understand the gamut of regulation across jurisdictions in order to lend lawfully to hemp-related businesses. Within its memorandum to members, the NCUA provided: 1) a summary of repercussions generated by the 2018 Farm…

The Blunt Truth

CBD is Everywhere – But Where Does the FDA Stand?

By Tonya M. Esposito, Renee B. Appel & Jonathan Huie on August 13, 2019

CBD is “thriving” in the current regulatory environment, but is it doing so illegally? As former U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb opined last week, “the CBD craze is getting out of hand. The FDA needs to act.” Since the passage of the Farm Bill in December of 2018, there has been a marked uptick in interest in the cannabidiol (CBD) space from businesses and users alike. Congress explicitly preserved…

The Blunt Truth

“C” is for…

By Tonya M. Esposito & Renee B. Appel on February 19, 2019

Cannabidiol (CBD) competed with Vitamin C as a top ingredient in new cosmetic products this past year, with promises of having anti-inflammatory effects and other healing properties. Amid the hype, at the end of 2018, the Agriculture Improvement Act of 2018, P.L. 115-334 (the “2018 Farm Bill”) was signed into law, changing the marketing of hemp and derivatives of cannabis and further removing hemp from the Controlled Substances Act thereby making it no longer an illegal substance under…

BioLoquitur

FDA Approves First Marijuana-Based Drug to Treat Epilepsy

By Tonya M. Esposito, Stanley Jutkowitz, Renee B. Appel & Robert Terzoli on July 5, 2018

On June 25, 2018, the Food and Drug Administration (“FDA”) approved Epidiolex (cannabidiol), the first marijuana derived drug for use in the United States, to treat two rare forms of epilepsy. This decision for the FDA could have sweeping effects for the marijuana industry. While the FDA has previously approved drugs comprising synthetic (manufactured) cannabinoids, this is the first FDA approved drug comprised of an active ingredient derived from marijuana. Even with FDA approval, further…

The Blunt Truth

FDA Approves First Marijuana-Based Drug to Treat Epilepsy

By Tonya M. Esposito, Stanley Jutkowitz, Renee B. Appel & Robert Terzoli on July 5, 2018

Consumer Class Defense Blog

Win Some, Lose Some: Trump Gets a Loss and a Win in the Fight to Control the CFPB

By Renee B. Appel, Esther Slater McDonald & Tonya M. Esposito on February 6, 2018

Seyfarth Synopsis: One court upholds protection of Dodd-Frank limiting the President’s removal authority, while another court stifles a challenge against Mulvaney serving as acting Director of CFPB. Last week, the Trump Administration experienced mixed results in the ongoing litigation over the Consumer Financial Protection Bureau (“CFPB”). As we’ve mentioned in our prior publications, there are several actions pending that involve the President’s authority to control the CFPB. The first action discussed below, which had…

Consumer Class Defense Blog

D.C. Circuit to Hear Appeal in Fight to Control CFPB

By Esther Slater McDonald, Tonya M. Esposito & Renee B. Appel on January 17, 2018

Seyfarth Synopsis: A federal judge on Wednesday denied a request to remove Mick Mulvaney as the CFPB’s acting director, finding that the President has authority to appoint the acting director despite former CFPB Director Cordray’s attempt to handpick his successor. On January 10, 2018, Judge Timothy Kelly of the U.S. District Court for the District of Columbia and a Trump Administration appointee denied Consumer Financial Protection Division (“CFPB”) Deputy Director Leandra English’s request for preliminary injunctive relief that would…

Renee B. Appel

FTC Issues Additional Three Warning Letters to CBD Companies

National Credit Union Administration Issues Statement About Serving Hemp Businesses

CBD is Everywhere – But Where Does the FDA Stand?

“C” is for…

FDA Approves First Marijuana-Based Drug to Treat Epilepsy

FDA Approves First Marijuana-Based Drug to Treat Epilepsy

Win Some, Lose Some: Trump Gets a Loss and a Win in the Fight to Control the CFPB

D.C. Circuit to Hear Appeal in Fight to Control CFPB

Company

Support

New to the Network